Expected reporting | |
RCTs | |
Large-scale RCT of theophylline added to ICS therapy | TWICS study n=1424 Expected to report 2016 ISCRTN 27066620 TASCS study n=2400 Expected to report 2016 NCT02261727 |
Large-scale RCT of roflumilast in those already on ICS/LABA | REACT study n=967 Expected to report 2015 NCT01329029 |
Large-scale cardiovascular safety of emerging ICS/LABA, LAMA and triple therapies in COPD patients with elevated cardiovascular risk | SUMMIT study n=16 000 Expected to report 2016–2017 NCT01313676 ASCENT study n=4000 Expected to report 2018–2019 NCT01966107 |
Further studies of triple therapy versus LABA/LAMA in GOLD groups B and C | |
Large-scale studies of MABA versus ICS/LABA/LAMA versus LABA/LAMA | |
Large-scale studies of biological therapies targeting ICS/LABA triple therapy-treated patients who still exacerbate | Benralizumab (GALATHEA study) n=1743 Expected to report 2017–2018 NCT02138916 |
Large-scale studies of novel anti-inflammatory agents (CXCR2 inhibitors, p38 MAPK inhibitors and PI3K inhibitors) | |
Pragmatic RCTs | |
Comparative study of new ICS/LABA to current standard therapy | Salford Lung Study n=7000 Expected to report 2016–2017 NCT01551758 |
Observational studies | |
Mortality and long-term safety studies of new therapies in patients with COPD and multiple comorbidities | |
Long-term safety and emergence of resistant pathogens with chronic macrolide use | |
Pneumonia risks in ICS-treated COPD patients already treated with pneumococcal vaccination |
RCT: randomised controlled trial; ICS: inhaled corticosteroids; TWICS: Theophylline with Inhaled Corticosteroid; ISRCTN: international standard randomised controlled trial number; TASCS: Theophylline and Steroids in Chronic Obstructive Pulmonary Disease Study; NCT: www.clinicaltrials.gov identifier number; LABA: long-acting β-agonist; LAMA: long-acting muscarinic antagonist; COPD: chronic obstructive pulmonary disease; SUMMIT: Study to Understand Mortality and Morbidity in COPD; GOLD: Global Initiative for Chronic Obstructive Lung Disease; MABA: muscarinic antagonist–β-agonist; MAP: mitogen-activated protein kinase; PI3K: phosphatidyl inositol 3-kinase.